Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Up 2.3 %

Shares of Trevena stock opened at $3.98 on Friday. Trevena has a 52-week low of $3.35 and a 52-week high of $25.75. The firm’s 50 day moving average price is $3.08 and its 200-day moving average price is $1.31. The company has a market cap of $3.38 million, a P/E ratio of -1.49 and a beta of 1.03.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.36. The business had revenue of $0.33 million during the quarter. As a group, equities research analysts forecast that Trevena will post -32.25 EPS for the current fiscal year.

Institutional Trading of Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC purchased a new stake in Trevena, Inc. (NASDAQ:TRVN) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena at the end of the most recent quarter. Institutional investors and hedge funds own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.